IRIS Accounts Production v26.2.0.496 08142934 director 1.1.25 31.12.25 31.12.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh081429342024-12-31081429342025-12-31081429342025-01-012025-12-31081429342023-12-31081429342024-01-012024-12-31081429342024-12-3108142934ns15:EnglandWales2025-01-012025-12-3108142934ns14:PoundSterling2025-01-012025-12-3108142934ns10:Director12025-01-012025-12-3108142934ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3108142934ns10:SmallEntities2025-01-012025-12-3108142934ns10:AuditExempt-NoAccountantsReport2025-01-012025-12-3108142934ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3108142934ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3108142934ns10:FullAccounts2025-01-012025-12-3108142934ns10:OrdinaryShareClass12025-01-012025-12-3108142934ns10:RegisteredOffice2025-01-012025-12-3108142934ns5:CurrentFinancialInstruments2025-12-3108142934ns5:CurrentFinancialInstruments2024-12-3108142934ns5:ShareCapital2025-12-3108142934ns5:ShareCapital2024-12-3108142934ns5:RetainedEarningsAccumulatedLosses2025-12-3108142934ns5:RetainedEarningsAccumulatedLosses2024-12-3108142934ns5:PlantMachinery2025-01-012025-12-3108142934ns5:PlantMachinery2024-12-3108142934ns5:PlantMachinery2025-12-3108142934ns5:PlantMachinery2024-12-3108142934ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-3108142934ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3108142934ns5:DeferredTaxation2024-12-3108142934ns5:DeferredTaxation2025-01-012025-12-3108142934ns5:DeferredTaxation2025-12-3108142934ns10:OrdinaryShareClass12025-12-3108142934ns5:RetainedEarningsAccumulatedLosses2024-12-3108142934ns5:RetainedEarningsAccumulatedLosses2025-01-012025-12-310814293412025-01-012025-12-31
REGISTERED NUMBER: 08142934 (England and Wales)












UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

DR. SILLIFANT AND ASSOCIATES LTD.

DR. SILLIFANT AND ASSOCIATES LTD. (REGISTERED NUMBER: 08142934)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


DR. SILLIFANT AND ASSOCIATES LTD.

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2025







DIRECTOR: Doctor K L Sillifant





REGISTERED OFFICE: Low Farm
New Road
Fritton
Great Yarmouth
Norfolk
NR31 9HT





REGISTERED NUMBER: 08142934 (England and Wales)





ACCOUNTANTS: Juler Tooke
Lothing House
Quay View Business Park
Barnards Way
Lowestoft
Suffolk
NR32 2HD

DR. SILLIFANT AND ASSOCIATES LTD. (REGISTERED NUMBER: 08142934)

BALANCE SHEET
31 DECEMBER 2025

31.12.25 31.12.24
Notes £    £   
FIXED ASSETS
Tangible assets 4 36,487 37,204

CURRENT ASSETS
Debtors 5 58,229 16,982
Cash at bank and in hand 24,219 69,587
82,448 86,569
CREDITORS
Amounts falling due within one year 6 (18,609 ) (21,546 )
NET CURRENT ASSETS 63,839 65,023
TOTAL ASSETS LESS CURRENT
LIABILITIES

100,326

102,227

PROVISIONS FOR LIABILITIES 7 (3,465 ) (2,837 )
NET ASSETS 96,861 99,390

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 9 96,761 99,290
SHAREHOLDERS' FUNDS 96,861 99,390

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 23 September 2026 and were signed by:



Doctor K L Sillifant - Director


DR. SILLIFANT AND ASSOCIATES LTD. (REGISTERED NUMBER: 08142934)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1. STATUTORY INFORMATION

Dr. Sillifant And Associates Ltd. is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on reducing balance, 15% on reducing balance and 10% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

DR. SILLIFANT AND ASSOCIATES LTD. (REGISTERED NUMBER: 08142934)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2025 54,763
Additions 5,526
At 31 December 2025 60,289
DEPRECIATION
At 1 January 2025 17,559
Charge for year 6,243
At 31 December 2025 23,802
NET BOOK VALUE
At 31 December 2025 36,487
At 31 December 2024 37,204

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.25 31.12.24
£    £   
Trade debtors 22,606 16,982
Other debtors 35,623 -
58,229 16,982

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.25 31.12.24
£    £   
Trade creditors 12,321 8,481
Taxation and social security 6,288 5,866
Other creditors - 7,199
18,609 21,546

7. PROVISIONS FOR LIABILITIES
31.12.25 31.12.24
£    £   
Deferred tax 3,465 2,837

Deferred
tax
£   
Balance at 1 January 2025 2,837
Provided during year 628
Balance at 31 December 2025 3,465

DR. SILLIFANT AND ASSOCIATES LTD. (REGISTERED NUMBER: 08142934)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.25 31.12.24
value: £    £   
100 Ordinary £1 100 100

9. RESERVES
Retained
earnings
£   

At 1 January 2025 99,290
Profit for the year 29,471
Dividends (32,000 )
At 31 December 2025 96,761

10. ULTIMATE CONTROLLING PARTY

The company was under the control of Dr K Sillifant as holder of the share capital throughout the current and
previous year.
The company operates a Loan account with the Directors and the balance as at 31 December 2025 was £(35,623) (31 December 2024 was £7,199).This overdrawn balance has been repaid since the year end